OBJECTIVE: Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy. CONCLUSION: Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.
OBJECTIVE: Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy. CONCLUSION: Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.
Authors: Dong-Joon Min; Yingdong Zhao; Anne Monks; Alida Palmisano; Curtis Hose; Beverly A Teicher; James H Doroshow; Richard M Simon Journal: Cancer Chemother Pharmacol Date: 2019-07-31 Impact factor: 3.333
Authors: Sriram Anbil; Imran Rizvi; Jonathan P Celli; Nermina Alagic; Brian W Pogue; Tayyaba Hasan Journal: J Biomed Opt Date: 2013-09 Impact factor: 3.170
Authors: Maryam Aghighi; Justin Boe; Jarrett Rosenberg; Rie Von Eyben; Rakhee S Gawande; Philippe Petit; Tarsheen K Sethi; Jeremy Sharib; Neyssa M Marina; Steven G DuBois; Heike E Daldrup-Link Journal: Radiology Date: 2016-03-16 Impact factor: 11.105
Authors: Wayne L Monsky; Bedro Jin; Chris Molloy; Robert J Canter; Chin Shang Li; Tzu C Lin; Daniel Borys; Walter Mack; Isaac Kim; Michael H Buonocore; Abhijit J Chaudhari Journal: Anticancer Res Date: 2012-11 Impact factor: 2.480
Authors: C G Vos; M Dahele; J R van Sörnsen de Koste; S Senan; I Bahce; M A Paul; E Thunnissen; E F Smit; K J Hartemink Journal: Strahlenther Onkol Date: 2013-12-22 Impact factor: 3.621